TrimRx's Blog
Semaglutide Insulin Resistance — How It Reverses the Core
Semaglutide improves insulin resistance by reducing hepatic glucose output up to 35% and increasing peripheral glucose uptake — reversing metabolic
Semaglutide Cholesterol — How GLP-1 Therapy Affects Lipids
Semaglutide reduces LDL cholesterol by 3–7% and triglycerides by 10–15% through weight loss, improved insulin sensitivity, and enhanced hepatic lipid
Semaglutide Prediabetes — Can GLP-1s Prevent Diabetes?
Semaglutide reduces prediabetes progression by 73% in clinical trials, preventing type 2 diabetes while improving weight and insulin sensitivity in
Semaglutide Heart Disease — Protection or Risk?
Semaglutide reduces cardiovascular events by 20% in high-risk patients but carries specific cardiac contraindications you must know before starting
Semaglutide Sleep Apnea — GLP-1 Impact on Breathing | TrimRx
Semaglutide reduces sleep apnea severity by 50–60% through weight loss and airway pressure reduction, with effects visible within 12–20 weeks of treatment.
Semaglutide Blood Pressure — Does It Help or Harm?
Semaglutide reduces systolic blood pressure by 5–8 mmHg on average through weight loss and improved insulin sensitivity—beyond what weight reduction alone
Semaglutide NAFLD — How GLP-1 Therapy Targets Liver Fat
Semaglutide NAFLD treatment shows 59% NASH resolution versus 17% placebo in clinical trials, targeting liver inflammation through mechanisms beyond weight
Semaglutide Cancer Risk — What the Evidence Actually Shows
Semaglutide cancer risk research shows no causal link in humans — animal thyroid tumor data doesn’t translate to clinical use. Here’s what matters.
Semaglutide Thyroid Cancer — What the Research Really Shows
Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies — but human clinical trials show no confirmed cases. Here’s what
